VTRS Viatris |
$8.81
+0.8% |
-5.7%
 |
meloxicam
For the Treatment of Moderate-to-Severe Acute Pain
|
Phase 3
|
8/1/2025 - Abstract
Viatris announced that five abstracts from its Phase 3 program evaluating novel fast-acting formula…
Full Summary
|
ALLO Allogene Therapeutics |
$1.08
-12.2% |
-10.0%
 |
Cemacabtagene Ansegedleucel
For Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse
|
|
8/1/2025 - Provided Update
Allogene Therapeutics, Inc announced that it has selected standard fludarabine and cyclophosphamide…
Full Summary
|
XCUR Exicure |
$7.05
-1.1% |
+18.3%
 |
burixafor
In Multiple Myeloma
|
Phase 2
|
8/1/2025 - Provided Update
Exicure, Inc announced it has completed the last patient, last visit in its ongoing Phase 2 clinical…
Full Summary
|
XCUR Exicure |
$7.05
-1.1% |
+18.3%
|
burixafor
In Multiple Myeloma
|
Target date: Q4 2025
|
8/1/2025 - Top-line results
Exicure, Inc. announced that the Topline results from the study are expected in the fourth quarter …
Full Summary
|
LLY Eli Lilly and Company |
$761.47
+2.9% |
-2.2%
 |
tirzepatide
For obesity or overweight with weight-related comorbidities, excluding type 2 diabetes.
|
Phase 3
|
7/31/2025 - Top-line results
Eli Lilly Announced Topline Results From SURPASS-CVOT Head-to-head Phase 3 Trial Comparing Mounjaro …
Full Summary
|
NVCT Nuvectis Pharma |
$6.80
-2.3% |
-9.6%
 |
NXP800
To treat platinum resistant, ARID1a-mutated ovarian carcinoma.
|
Phase 1b
|
7/31/2025 - Clinical Update
Nuvectis Pharma, Inc. today provided the final clinical data update from the Phase 1b study of NXP8…
Full Summary
|
AVXL Anavex Life Sciences |
$11.20
-0.9% |
+6.0%
 |
ANAVEX®2-73-AD-EP-004
for the potential treatment of early Alzheimer's disease.
|
|
7/31/2025 - Findings Update
Anavex Life Sciences Corp announced the latest findings for blarcamesine, an oral small molecule fo…
Full Summary
|
FDMT 4D Molecular Therapeutics |
$6.42
+42.7% |
+49.0%
 |
4D-150
Intravitreal vector, R100, and a transgene payload that expresses both aflibercept and a VEGF-C inhibitory RNAi.
|
|
7/31/2025 - Positive Results
4D Molecular Therapeutics announced positive results from the SPECTRA clinical trial evaluating 4D-1…
Full Summary
|
LTRN Lantern Pharma |
$4.77
+7.4% |
+50.0%
 |
RADR
AI platform to accelerate and optimize the development of antibody-drug conjugates (ADCs).
|
Phase 2
|
7/31/2025 - Enrollment Completion
Lantern Pharma Inc. ( announced the successful completion of targeted enrollment for its Phase 2 HAR…
Full Summary
|
BGNE BeiGene |
|
|
BGB-16673
For adult patients with relapsed or refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL)
|
PRIority MEdicines (PRIME) designation
|
7/31/2025 - Designation Grant
BeOne Medicines announced that the European Medicines Agency (EMA) has granted PRIority MEdicines (…
Full Summary
|
EOLS Evolus |
$9.15
+2.6% |
-0.7%
 |
Jeuveau
Aesthetics
|
|
7/31/2025 - Publication
Evolus, Inc. announced the publication of a landmark independent study in JAMA Dermatology directly…
Full Summary
|
TIL Instil Bio |
$22.23
-7.4% |
-6.6%
 |
IMM2510/AXN-2510
For front-line patients with advanced non-small cell lung cancer (NSCLC)
|
Phase 2
|
7/31/2025 - Efficacy and Safety Data
Instil Bio, Inc. announced preliminary safety and efficacy data from the Phase 2 open-label, multic…
Full Summary
|
RARE Ultragenyx Pharmaceutical |
$28.44
+4.1% |
-27.9%
 |
GTX-102 (PP)
Pediatric patients with Angelman syndrome in Canada
|
Phase 3
|
7/31/2025 - Enrollment Update
Ultragenyx Pharmaceutical announced that the Phase 3 Aspire study evaluating GTX-102 (apazunersen) …
Full Summary
|
LLY Eli Lilly and Company |
$761.47
+2.9% |
-2.2%
|
donanemab-azbt
In early symptomatic Alzheimer's disease
|
Phase 3
|
7/30/2025 - Results
Eli Lilly and Company announced results from the long-term extension (LTE) of the Phase 3 TRAILBLAZ…
Full Summary
|
MIRA MIRA Pharmaceuticals |
$1.54
-6.7% |
+24.2%
 |
Ketamir-2
To treat depression and treatment-resistant depression (TRD).
|
|
7/30/2025 - Preclinical Data
MIRA Pharmaceuticals, announced new preclinical data showing that its topical Ketamir-2 cream delive…
Full Summary
|
CRBP Corbus Pharmaceuticals |
$9.31
+0.4% |
+20.1%
 |
CRB-701
Targets the expression of Nectin-4 on cancer cells
|
|
7/30/2025 - Abstract
Corbus Pharmaceuticals announced that an abstract on updated clinical data from its Phase 1/2 clini…
Full Summary
|
SNY Sanofi |
$46.75
+2.4% |
-5.2%
 |
Libtayo (cemiplimab)
Advanced Cervical Cancer
|
Phase 1/2
|
7/30/2025 - Clinical Data
Sensei Biotherapeutics, Inc that clinical data from the dose expansion cohort of the Phase 1/2 trial…
Full Summary
|
BVS Bioventus |
$6.18
-5.2% |
|
TalisMann
For chronic pain management.
|
|
7/30/2025 - Provided Update
Bioventus Inc announced today a significant milestone with the U.S. Food and Drug Administration (FD…
Full Summary
|
REGN Regeneron Pharmaceuticals |
$558.87
+2.5% |
+2.0%
 |
Libtayo (cemiplimab)
Advanced Cervical Cancer
|
Phase 1/2
|
7/30/2025 - Clinical Data
Sensei Biotherapeutics, Inc that clinical data from the dose expansion cohort of the Phase 1/2 trial…
Full Summary
|
IXHL Incannex Healthcare |
$0.39
-34.1% |
+86.3%
 |
IHL-42X
Obstructive Sleep Apnoea (OSA)
|
|
7/30/2025 - Top-line results
Incannex Healthcare Inc is excited to share positive topline results from its RePOSA Phase 2 clinic…
Full Summary
|
TNYA Tenaya Therapeutics |
$0.67
-0.8% |
+9.4%
 |
TN-201
Fully functional MYBPC3 gene
|
|
7/30/2025 - Provided Update
Tenaya Therapeutics, Inc announced positive endorsements from each trial's independent Data Safety a…
Full Summary
|
BIIB Biogen |
$131.95
+3.1% |
-0.9%
 |
LEQEMBI® (lecanemab-irmb)
Treatment of Alzheimer's Disease
|
|
7/30/2025 - Results
Eisai Co., Ltd. and Biogen Inc announced that results on investigational maintenance therapy with…
Full Summary
|
ANIK Anika Therapeutics |
$8.64
+4.6% |
-23.2%
 |
Hyalofast
Intended as support for the entrapment of mesenchymal stem cells obtained from autologous bone marrow aspirate concentrate (BMAC) for the repair of chondral and osteochondral lesions.
|
|
7/30/2025 - Top-line results
Anika Therapeutics, Inc. announced topline results from its U.S. pivotal clinical trial of Hyalofas…
Full Summary
|
NAMS NewAmsterdam Pharma |
$21.28
-2.4% |
+12.2%
 |
LDL-C
For Alzheimer's Disease
|
|
7/30/2025 - Data
NewAmsterdam Pharma Company N.V announced full data from the prespecified Alzheimer's disease ("AD")…
Full Summary
|
BDX Becton, Dickinson and Company |
$176.19
-1.2% |
-0.5%
 |
BD Veritor™ System
For SARS-CoV-2
|
|
7/30/2025 - FDA Clearance
BD (Becton, Dickinson and Company) announced that it has received U.S. Food and Drug Administration …
Full Summary
|
ABBV AbbVie |
$195.17
+3.3% |
+2.3%
 |
RINVOQ (upadacitinib)
Moderate to Severe Atopic Dermatitis
|
|
7/30/2025 - Top-line results
AbbVie announced positive topline results from the first of two pivotal studies of the Phase 3 UP-AA…
Full Summary
|
LLY Eli Lilly and Company |
$761.47
+2.9% |
-2.2%
|
Pirtobrutinib
A non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, in adult
|
Phase 3
|
7/29/2025 - Top-line results
Eli Lilly and Company announced positive topline results from the Phase 3 BRUIN CLL-314 clinical tr…
Full Summary
|
CGTX Cognition Therapeutics |
$0.67
+13.9% |
+99.1%
 |
CT1812
Designed to penetrate the blood-retinal barrier and bind selectively and saturably to the σ-2 receptor complex.
|
Phase 2
|
7/29/2025 - Results
Cognition Therapeutics, presented results from the Phase 2 COG1201 SHIMMER study (NCT05225415) of z…
Full Summary
|
JNJ Johnson & Johnson |
$167.33
+1.6% |
+7.5%
 |
Guselkumab
For Treatment Of Adults With Moderately To Severely Active Ulcerative Colitis
|
sBLA
|
7/29/2025 - sBLA Filing
Johnson & Johnson announced the submission of a supplemental Biologics License Application (sBLA) t…
Full Summary
|
ACRS Aclaris Therapeutics |
$1.53
|
+5.5%
 |
ATI-2138
For the Treatment of Moderate to Severe Atopic Dermatitis
|
Phase 2a
|
7/29/2025 - Top-line results
Aclaris Therapeutics, Inc. announced positive top-line results from its open-label, single-arm Phas…
Full Summary
|
EYPT Eyepoint Pharmaceuticals |
$9.71
-1.1% |
+0.5%
 |
DURAVYU
In patients with non-proliferative diabetic retinopathy (NPDR).
|
Phase 3
|
7/29/2025 - Enrollment Update
EyePoint Pharmaceuticals, Inc. announced it has completed enrollment of its Phase 3 pivotal program…
Full Summary
|
SGHT Sight Sciences |
$3.27
-1.8% |
-21.4%
 |
TearCare System
Meibomian Gland Dysfunction (MGD)
|
|
7/29/2025 - Results
Sight Sciences, Inc. announced that the manuscript detailing 24-month results from Stage 3 of the SA…
Full Summary
|
FULC Fulcrum Therapeutics |
$6.83
+1.5% |
-1.4%
 |
pociredir
In sickle cell disease
|
|
7/29/2025 - Positive Results
Fulcrum Therapeutics, today reported positive results from the 12 mg dose cohort of the Phase 1b PIO…
Full Summary
|
ABBV AbbVie |
$195.17
+3.3% |
+2.3%
|
venetoclax
For Newly Diagnosed Higher-Risk Myelodysplastic Syndromes
|
supplemental New Drug Application (sNDA)
|
7/29/2025 - sNDA Filing
AbbVie announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and …
Full Summary
|
ONCY Oncolytics Biotech |
$0.99
-2.9% |
+25.7%
 |
Pelareorep
In Breast Cancer
|
|
7/29/2025 - Provided Update
Oncolytics Biotech® Inc. Assuming discussions with the FDA go as expected, the Company expects to c…
Full Summary
|
MIRA MIRA Pharmaceuticals |
$1.54
-6.7% |
+24.2%
|
Ketamir-2
To treat depression and treatment-resistant depression (TRD).
|
IND
|
7/29/2025 - FDA Clearance
MIRA Pharmaceuticals, announced that the U.S. Food and Drug Administration (FDA) has cleared its Inv…
Full Summary
|
ONCY Oncolytics Biotech |
$0.99
-2.9% |
+25.7%
|
Pelareorep
In Breast Cancer
|
|
7/29/2025 - Regulatory Update
Oncolytics Biotech® Inc announced it has initiated regulatory discussions with the U.S. Food and Dru…
Full Summary
|
NKTR Nektar Therapeutics |
$22.96
+5.9% |
-10.1%
 |
Rezpegaldesleukin
For the treatment of atopic dermatitis.
|
Fast Track
|
7/29/2025 - Designation Grant
Nektar Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast T…
Full Summary
|
ATOS Atossa Genetics |
$0.82
-1.3% |
-1.7%
 |
endoxifen-Z
for Breast Cancer
|
|
7/29/2025 - Feedback
Atossa Therapeutics, Inc. announced positive written feedback from the U.S. Food and Drug Administr…
Full Summary
|
DARE Dare Bioscience |
$2.42
+0.8% |
+0.8%
 |
Sildenafil Cream
Women with Female Sexual Arousal Disorder
|
Phase 1
|
7/29/2025 - Provided Update
Daré Bioscience, Inc. announced the launch of the first phase of a consumer awareness campaign to s…
Full Summary
|
HOTH Hoth Therapeutics |
$1.31
-1.9% |
+8.8%
 |
HT-001
Cancer patients suffering from cutaneous toxicities (skin, nails, scalp) due to EGFR
|
Phase 2
|
7/29/2025 - Clinical Trial
Hoth Therapeutics, Inc announced its engagement with ICON Clinical Research Limited ("ICON") to expa…
Full Summary
|
CING Cingulate |
$5.10
-1.5% |
+17.5%
 |
CTx-1301
Attention Deficit/Hyperactivity Disorder (ADHD)
|
NDA
|
7/29/2025 - Provided Update
Cingulate Inc. announced that it has received a fiscal year 2025 PDUFA (Prescription Drug User Fee A…
Full Summary
|
CRDF Cardiff Oncology |
$2.64
+11.4% |
-26.5%
 |
CRDF-004
RAS-mutated mCRC.
|
Phase 2
|
7/29/2025 - Positive Data
Cardiff Oncology, Inc. announced positive data from the ongoing CRDF-004, a randomized, Phase 2 clin…
Full Summary
|
CELC Celcuity |
$39.91
+1.9% |
+206.1%
 |
Gedatolisib
HR+ / HER2- Metastatic Breast Cancer
|
Phase 1b
|
7/28/2025 - Top-line results
Celcuity Inc reported topline results from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 tri…
Full Summary
|
RNA Avidity Biosciences |
$35.92
-2.2% |
+22.3%
 |
del-desiran
for Treatment of Myotonic Dystrophy Type 1
|
Target date: Q4 2025
|
7/28/2025 - Efficacy and Safety Data
Avidity Biosciences, Inc. announced that On track to share updates from ongoing MARINA-OLE™ trial of…
Full Summary
|
BGNE BeiGene |
|
|
TEVIMBRA
For the first-line treatment of patients with locally advanced unresectable or metastatic esophageal squamous cell carcinoma (ESCC)
|
EMA
|
7/28/2025 - Positive Opinion
BeOne Medicines Ltd announced that the Committee for Medicinal Products for Human Use (CHMP) of the…
Full Summary
|
ASND Ascendis Pharma A/S |
$174.48
+0.6% |
+0.8%
 |
SKYTROFA®
For the Once-Weekly Treatment of Children and Adolescents with Growth Hormone Deficiency
|
|
7/28/2025 - FDA approved
Ascendis Pharma announced that the U.S. Food & Drug Administration (FDA) has approved SKYTROFA® (lo…
Full Summary
|
CELC Celcuity |
$39.91
+1.9% |
+206.1%
|
Gedatolisib
HR+ / HER2- Metastatic Breast Cancer
|
|
7/28/2025 - Top-line results
Celcuity Inc announced positive topline results from the PIK3CA wild-type cohort of the Phase 3 VIK…
Full Summary
|
URGN Urogen Pharma |
$19.40
+1.8% |
+49.7%
 |
UGN-102
Low-grade, intermediate-risk, Non-muscle invasive bladder cancer (NMIBC)
|
Phase 3b
|
7/28/2025 - Publication
UroGen Pharma Ltd. announced the publication in Reviews in Urology of results from a Phase 3b study…
Full Summary
|
MRNA Moderna |
$27.60
-6.6% |
-8.9%
 |
mRNA-4359
Inhibitor-Resistant/Refractory (CPI-R/R) Melanoma
|
|
7/28/2025 - Abstract
Moderna, Inc. announced that three abstracts on its investigational mRNA therapeutics have been acc…
Full Summary
|
ZYME Zymeworks |
$12.57
+0.1% |
-2.5%
 |
ZW251
In hepatocellular carcinoma models
|
NDA
|
7/28/2025 - FDA Clearance
Zymeworks announced the U.S. Food and Drug Administration (FDA) has cleared the investigational new…
Full Summary
|
FULC Fulcrum Therapeutics |
$6.83
+1.5% |
-1.4%
|
pociredir
In sickle cell disease
|
|
7/28/2025 - Top-line results
Fulcrum Therapeutics to present topline results from the 12 mg dose cohort of the Phase 1b PIONEER …
Full Summary
|
SRPT Sarepta Therapeutics |
$15.91
-3.1% |
-12.5%
 |
ELEVIDYS (delandistrogene moxeparvovec-rokl)
Designed to address the underlying cause of Duchenne muscular dystrophy through the targeted production of ELEVIDYS micro-dystrophin in skeletal muscle.
|
|
7/28/2025 - FDA Notification
Sarepta Therapeutics, Inc announced that the U.S. Food and Drug Administration (FDA) notified Sarep…
Full Summary
|
ABOS Acumen Pharmaceuticals |
$1.35
-3.6% |
+19.5%
 |
Sabirnetug
for Early Alzheimer's Disease
|
|
7/28/2025 - Results
Acumen Pharmaceuticals, announced results showing that implementing a blood-based pTau217 screening…
Full Summary
|
ATHE Alterity Therapeutics |
$5.01
-1.0% |
+24.0%
 |
ATH434-202
In Multiple System Atrophy
|
|
7/28/2025 - Top-line data
Alterity Therapeutics announced positive topline data from the ATH434-202 open-label Phase 2 clinic…
Full Summary
|
AZN AstraZeneca |
$73.95
+1.2% |
+4.0%
 |
Durvalumab
Treatment Of Locally Advanced Or Metastatic Biliary Tract Cancer In Combination With Chemotherapy
|
sBLA Priority Review
|
7/28/2025 - FDA GRANT
AstraZeneca announced that supplemental Biologics License Application (sBLA) for Imfinzi (durvaluma…
Full Summary
|
ENLV Enlivex Therapeutics |
$1.45
-2.7% |
+28.3%
 |
Allocetra
Sepsis
|
Phase 2
|
7/28/2025 - Provided Update
Enlivex Therapeutics Ltd announced that all 134 patients in its Phase II stage of its randomized, co…
Full Summary
|
CGEN Compugen |
$1.48
+2.1% |
-14.9%
 |
COM701
Solid tumors
|
Phase 1
|
7/28/2025 - Data Presentation
Compugen Ltd. announced that it will present a pooled analysis of data from three Phase 1 trials eva…
Full Summary
|
RADX Radiopharm Theranostics |
$5.35
+13.8% |
+31.8%
 |
RV-01
For the 4Ig isoform
|
IND
|
7/28/2025 - FDA Clearance
Radiopharm Theranostics announced that the U.S. Food and Drug Administration (FDA) has provided cle…
Full Summary
|
ATHE Alterity Therapeutics |
$5.01
-1.0% |
+24.0%
|
ATH434
To inhibit the aggregation of pathological proteins implicated in neurodegeneration
|
Phase 2
|
7/28/2025 - Top-line data
Alterity Therapeutics announced positive topline data from the ATH434-202 open-label Phase 2 clinica…
Full Summary
|
MIRA MIRA Pharmaceuticals |
$1.54
-6.7% |
+24.2%
|
Ketamir-2
To treat depression and treatment-resistant depression (TRD).
|
IND
|
7/28/2025 - FDA Clearance
MIRA Pharmaceuticals, Inc announced that the U.S. Food and Drug Administration (FDA) has cleared it…
Full Summary
|
REGN Regeneron Pharmaceuticals |
$558.87
+2.5% |
+2.0%
|
Semaglutide (GLP-1 receptor agonist)
induced Weight Loss by Preserving Lean Mass
|
Phase 1b
|
7/28/2025 - Positive Results
Lexaria Bioscience Corp. provides the following partial 8-week positive interim results update on t…
Full Summary
|
RNA Avidity Biosciences |
$35.92
-2.2% |
+22.3%
|
del-desiran
for Treatment of Myotonic Dystrophy Type 1
|
Phase 3
Target date: Q2 2026
|
7/28/2025 - Top-line data
Avidity Biosciences, Inc. announced that Topline data from HARBOR, the first global Phase 3 clinical…
Full Summary
|
APLS Apellis Pharmaceuticals |
$22.95
+2.7% |
+28.8%
 |
pegcetacoplan
Paroxysmal nocturnal hemoglobinuria (PNH)
|
FDA Approved
|
7/28/2025 - FDA approved
Apellis Pharmaceuticals, announced that the U.S. Food and Drug Administration (FDA) has approved EM…
Full Summary
|
ENTX Entera Bio |
$1.95
+1.0% |
+2.1%
 |
EB613
Parathyroid hormone (1-34), or PTH for osteoporosis
|
Type A Meeting
|
7/28/2025 - Provided Update
Entera Bio Ltd. announced that in a written response to a Type A meeting request, the U.S. Food an…
Full Summary
|
IMMP Prima BioMed |
$1.72
-1.1% |
+1.2%
 |
eftilagimod alpha
For cancer and autoimmune disease
|
|
7/28/2025 - Abstract
Immutep Limited announces three abstracts for clinical trials evaluating its first-in-class MHC Cla…
Full Summary
|
RNXT RenovoRx |
$1.21
-2.4% |
-6.9%
 |
RenovoCath
Solid Tumors
|
|
7/28/2025 - Provided Update
RenovoRx, Inc. announced the launch of the PanTheR Post-Marketing Registry Study (NCT06805461).
Full Summary
|
PRQR ProQR Therapeutics |
$2.08
-1.0% |
-2.3%
 |
Axiomer
Editing Technology Adenosine Deaminase Acting on RNA)
|
|
7/28/2025 - Provided Update
ProQR Therapeutics NV announced that it will participate in the RNA Editing Summit taking place Jul…
Full Summary
|
RNA Avidity Biosciences |
$35.92
-2.2% |
+22.3%
|
del-desiran
for Treatment of Myotonic Dystrophy Type 1
|
Phase 3
|
7/28/2025 - Enrollment Completion
Avidity Biosciences, Inc. announced the completion of enrollment in the ongoing global Phase 3 HARB…
Full Summary
|
ASMB Assembly Biosciences |
$18.40
+2.7% |
+0.5%
 |
ABI-5366
For recurrent genital herpes.
|
Phase 1a
|
7/26/2025 - Poster Presentation
Assembly Biosciences, Inc announced Phase 1a clinical and preclinical data for its herpes simplex vi…
Full Summary
|
SAGE Sage Therapeutics |
$8.69
-0.2% |
-4.3%
 |
Zuranolone
Major depressive disorder (MDD) and Postpartum depression (PPD)
|
|
7/25/2025 - Positive Opinion
Biogen Inc. announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medi…
Full Summary
|
IONS Ionis Pharmaceuticals |
$43.03
+0.1% |
-1.3%
 |
Olezarsen (Formerly IONIS-APOCIII-L)
Severe hypertriglyceridemia
|
EMA
|
7/25/2025 - Positive Opinion
Ionis Pharmaceuticals, Inc and Sobi® today announced that the Committee for Medicinal Products for …
Full Summary
|
KRYS Krystal Biotech |
$156.98
+2.0% |
+11.1%
 |
VYJUVEK
Designed to treat DEB at the molecular level by providing the patient's skin cells the template to make normal COL7 protein,
|
|
7/25/2025 - Marketing authorization
Krystal Biotech, Inc announced today that on July 24, 2025, Japan's Ministry of Health, Labour and …
Full Summary
|
SRPT Sarepta Therapeutics |
$15.91
-3.1% |
-12.5%
|
ELEVIDYS (delandistrogene moxeparvovec-rokl)
Designed to address the underlying cause of Duchenne muscular dystrophy through the targeted production of ELEVIDYS micro-dystrophin in skeletal muscle.
|
|
7/25/2025 - Negative opinion
Sarepta Therapeutics, Inc the leader in precision genetic medicine for rare diseases, acknowledges t…
Full Summary
|
PFE Pfizer |
$23.49
+0.9% |
-7.2%
 |
COMIRNATY® LP.8.1
For active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older.
|
EMA
|
7/25/2025 - Marketing authorization
Pfizer Inc. announced that the European Medicines Agency's (EMA) Committee for Medicinal Products …
Full Summary
|
KALV KalVista Pharmaceuticals |
$13.21
-3.1% |
+12.1%
 |
sebetralstat
Therapy for hereditary angioedema (HAE).
|
EMA
|
7/25/2025 - Positive Opinion
KalVista Pharmaceuticals, Inc. announced that the Committee for Medicinal Products for Human Use (CH…
Full Summary
|
IONS Ionis Pharmaceuticals |
$43.03
+0.1% |
-1.3%
|
Olezarsen (Formerly IONIS-APOCIII-L)
Severe hypertriglyceridemia
|
Target date: Q4 2025
|
7/25/2025 - Provided Update
Ionis Pharmaceuticals, Inc and Sobi announced that European Commission decision expected by Q4 2025
Full Summary
|
LLY Eli Lilly and Company |
$761.47
+2.9% |
-2.2%
|
Donanemab
Alzheimer's disease (AD)
|
EMA
|
7/25/2025 - Positive Opinion
Eli Lilly and Company announced that that the European Medicines Agency's (EMA) Committee for Medic…
Full Summary
|
BIIB Biogen |
$131.95
+3.1% |
-0.9%
|
Zuranolone
Major depressive disorder (MDD) and Postpartum depression (PPD)
|
|
7/25/2025 - Positive Opinion
Biogen Inc. announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medi…
Full Summary
|
GILD Gilead Sciences |
$113.18
+0.8% |
+1.5%
 |
Lenacapavir
For the treatment of HIV infection
|
EMA
|
7/25/2025 - Positive Opinion
Gilead Sciences, Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of t…
Full Summary
|
KALV KalVista Pharmaceuticals |
$13.21
-3.1% |
+12.1%
|
sebetralstat
Therapy for hereditary angioedema (HAE).
|
Target date: October 01, 2025
|
7/25/2025 - Provided Update
KalVista Pharmaceuticals, Inc. announced that European Commission decision expected by early Octobe…
Full Summary
|
MRNA Moderna |
$27.60
-6.6% |
-8.9%
|
SPIKEVAX (COVID-19 Vaccine, mRNA)
COVID-19 in individuals 18 years of age and older
|
EMA
|
7/25/2025 - Positive Opinion
Moderna, Inc. announced that the European Medicines Agency's (EMA) Committee for Medicinal Products …
Full Summary
|
MNOV MediciNova |
$1.43
+7.9% |
+12.6%
 |
MN-166 (ibudilast)
Inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines
|
|
7/24/2025 - Enrollment Update
MediciNova, Inc. today provides an update on the enrollment of two key ongoing clinical trials for …
Full Summary
|
ANNX Annexon |
$2.45
+2.1% |
-12.8%
 |
ANX007
Geographic Atrophy
|
Phase 3
|
7/24/2025 - Enrollment Update
Annexon, Inc. announced complete enrollment of the Phase 3 ARCHER II trial of vonaprument (formerly …
Full Summary
|
ACET Adicet Bio |
$0.67
-2.2% |
+9.2%
 |
ADI-001
B cell non-Hodgkin's lymphoma (NHL)
|
Phase 1
|
7/24/2025 - Data Presentation
Adicet Bio, Inc announced that the first systemic sclerosis (SSc) patient has been dosed in the seco…
Full Summary
|
ALMS Alumis |
$4.13
-0.2% |
+25.9%
 |
ESK-001
In Moderate-to-Severe Plaque Psoriasis
|
Target date: Q3 2026
|
7/24/2025 - Topline Readout
Alumis Inc. announced that Topline Readout Expected in Q3 2026
Full Summary
|
INMB INmune Bio |
$2.56
-6.2% |
+8.5%
 |
XPro
For treatment of Alzheimer's Disease
|
Phase 2
|
7/24/2025 - Analysis
INmune Bio Inc announced that additional analyses from its Phase 2 MINDFuL trial evaluating XPro™, a…
Full Summary
|
IDYA IDEAYA Biosciences |
$24.27
-0.3% |
+10.7%
 |
Darovasertib
Non-metastatic uveal melanoma (UM)
|
Phase 2
|
7/24/2025 - Results
IDEAYA Biosciences, Inc. announced that results from a multi-site global Phase 2 study of neoadjuva…
Full Summary
|
AZN AstraZeneca |
$73.95
+1.2% |
+4.0%
|
gefurulimab
in adults with generalised myasthenia gravis
|
Phase 3
|
7/24/2025 - Endpoint Met
AstraZeneca announced Positive high-level results from a global, randomised, double-blind, placebo-c…
Full Summary
|
NTRA Natera |
$134.58
+0.7% |
-16.7%
 |
Prospera
CfDNA testing
|
|
7/24/2025 - Findings Update
Natera, Inc. announced that the American Journal of Transplantation published findings from the PEDA…
Full Summary
|
ALDX Aldeyra Therapeutics |
$4.81
-3.6% |
+20.3%
 |
ADX-2191
Primary vitreoretinal lymphoma (PVRL)
|
Orphan Drug
|
7/24/2025 - Designation Grant
Aldeyra Therapeutics, Inc. announced that the European Medicines Agency (EMA) has granted Orphan De…
Full Summary
|
ATRA Atara Biotherapeutics |
$11.55
+0.3% |
+40.0%
 |
Tabelecleucel (tab-cel)
Post-Transplant Lymphoproliferative Disease (PTLD)
|
BLA
Target date: January 10, 2026
|
7/24/2025 - PDUFA Date
Atara Biotherapeutics, Inc announced that Prescription Drug User Fee Act (PDUFA) Target Action Date…
Full Summary
|
VIR Vir Biotechnology |
$5.03
-0.8% |
-7.4%
 |
VIR-5525
For the Treatment of Solid Tumors
|
Phase 1
|
7/24/2025 - Dose Update
Vir Biotechnology, Inc announced that the first patient has been dosed in the Company's Phase 1 clin…
Full Summary
|
ELAN Elanco Animal Health |
$13.80
+0.9% |
-6.3%
 |
Zenrelia
Treatment for canine allergic itch and inflammation
|
EC Approval
|
7/24/2025 - Approved
Elanco Animal Health Incorporated announced that Zenrelia™ (ilunocitinib) has received approval by…
Full Summary
|
JNJ Johnson & Johnson |
$167.33
+1.6% |
+7.5%
|
posdinemab
For Alzheimer's disease
|
|
7/24/2025 - Promising data
Johnson & Johnson announced promising new data from its Alzheimer's disease (AD) research program wi…
Full Summary
|
ATRA Atara Biotherapeutics |
$11.55
+0.3% |
+40.0%
|
Tabelecleucel (tab-cel)
Post-Transplant Lymphoproliferative Disease (PTLD)
|
BLA
|
7/24/2025 - FDA Accepted
Atara Biotherapeutics, Inc announced that the U.S. Food and Drug Administration (FDA) has accepted t…
Full Summary
|
BCDA BioCardia |
$2.13
-0.5% |
+2.4%
 |
CardiAMP
Designed to be a comprehensive biotherapeutic heart failure solution
|
|
7/24/2025 - Provided Update
BioCardia®, Inc announced that it submitted its CardiAMP autologous cell therapy investigational he…
Full Summary
|
ALMS Alumis |
$4.13
-0.2% |
+25.9%
|
ESK-001
In Moderate-to-Severe Plaque Psoriasis
|
Phase 2b
|
7/24/2025 - Enrollment Completion
Alumis Inc. announced the completion of patient enrollment in its global LUMUS Phase 2b trial of ESK…
Full Summary
|
NVAX Novavax |
$6.56
-1.4% |
-3.0%
 |
Matrix-M
for its COVID-19-Influenza Combination (CIC) and stand-alone influenza vaccine candidates.
|
|
7/24/2025 - Preclinical Data
Novavax, Inc. announced preclinical data demonstrating that Novavax's H5N1 avian pandemic influenza …
Full Summary
|
CADL Candel Therapeutics |
$6.29
-2.5% |
+26.1%
 |
CAN-2409
Prostate cancer
|
Orphan Drug
|
7/24/2025 - Designation Grant
Candel Therapeutics, Inc. announced that the European Medicines Agency (EMA) has granted Orphan Des…
Full Summary
|
